- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Avacta Group PLC (AVCT)
Avacta Group PLC stock price live, this page displays LON AVCT stock exchange data. View the AVCT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Avacta Group PLC real time stock price chart below.
What Is the Avacta Group PLC Stock Price Today?
The Avacta Group PLC stock price today is 65.25.
What Is the Stock Symbol for Avacta Group PLC?
The stock symbol for Avacta Group PLC is "AVCT."
What Stock Exchange Does Avacta Group PLC Trade On?
Avacta Group PLC is listed and trades on the London stock exchange.
Is Avacta Group PLC a Good Stock to Buy?
Determining whether Avacta Group PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVCT quote. (ISIN: GB00BYYW9G87)
What Is the Avacta Group PLC Stock Price Today?
The Avacta Group PLC stock price today is 65.25.
What Is the Stock Symbol for Avacta Group PLC?
The stock symbol for Avacta Group PLC is "AVCT."
What Stock Exchange Does Avacta Group PLC Trade On?
Avacta Group PLC is listed and trades on the London stock exchange.
Is Avacta Group PLC a Good Stock to Buy?
Determining whether Avacta Group PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVCT quote. (ISIN: GB00BYYW9G87)
65.25
-0.25(-0.38%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.00
67.00
52 wk Range
46.00
92.00
AVCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.0067.00
52 wk Range
46.0092.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
AVCT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
81.67
Upside
+25.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Short term obligations exceed liquid assets
Avacta posts 2025 annual report, schedules June AGM- Investing.com
- Avacta posts 2025 annual report, schedules June AGM
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 81.67
(+25.16% Upside)
Avacta Group PLC Earnings Call Summary for H2/2025
- Avacta raised £32.5M over 18 months, extending cash runway to early Q1 2027; net cash balance at £16.4M as of April 2026.
- R&D expenses rose 31.5% YoY to £18.8M, reflecting strategic focus on pre|CISION oncology platform development.
- Administrative costs declined 16.7% to £10M through cost reduction initiatives; net operating cash outflows improved to £22.64M.
- Company considering dual Nasdaq listing to attract U.S. investors; remains clinical-stage with no current revenue generation.
- FY2025-26 EPS guidance at -$0.09 and -$0.08 respectively; management optimistic on clinical trials despite commercialization uncertainties.
Last Updated: 05/19/2026, 10:24 PM
Read Full TranscriptEarnings
Latest Release
May 19, 2026
EPS / Forecast
-0.05 / --
Revenue / Forecast
57K / --
Compare AVCT to Peers and Sector
Metrics to compare | AVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.5x | −4.1x | −0.3x | |
PEG Ratio | −0.23 | −0.06 | 0.00 | |
Price/Book | 123.9x | 2.0x | 2.6x | |
Price / LTM Sales | 2,715.1x | 8.8x | 3.1x | |
Upside (Analyst Target) | 29.0% | 165.3% | 50.4% | |
Fair Value Upside | Unlock | −1.4% | 6.4% | Unlock |
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company’s lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Avacta Group (AVCT) Stock Price Today?
The Avacta Group stock price today is 65.25 GBP.
What Stock Exchange Does Avacta Group Trade On?
Avacta Group is listed and trades on the London Stock Exchange.
What Is the Stock Symbol for Avacta Group?
The stock symbol for Avacta Group is "AVCT."
What Is the Avacta Group Market Cap?
As of today, Avacta Group market cap is 304.46M GBP.
What Is Avacta Group's Earnings Per Share (TTM)?
The Avacta Group EPS (TTM) is -0.09.
When Is the Next Avacta Group Earnings Date?
Avacta Group will release its next earnings report on Oct 05, 2026.
From a Technical Analysis Perspective, Is AVCT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Avacta Group Stock Split?
Avacta Group has split 1 times.
How Many Employees Does Avacta Group Have?
Avacta Group has 81 employees.
What is the current trading status of Avacta Group (AVCT)?
As of Aug 19, 2026, Avacta Group (AVCT) is trading at a price of 65.25 GBP, with a previous close of 65.50 GBP. The stock has fluctuated within a day range of 64.00 GBP to 67.00 GBP, while its 52-week range spans from 46.00 GBP to 92.00 GBP.
What Is Avacta Group (AVCT) Price Target According to Analysts?
The average 12-month price target for Avacta Group is 81.67 GBP, with a high estimate of 101 GBP and a low estimate of 60 GBP. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +25.16% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.